Pharmacopeia
Master Compare
Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.
| Field |
ACICLOVIR
Anti-infectives · Anti-infectives · Level 3
|
NEURAMINIDASE INHIBITORS
Anti-infectives · Anti-infectives · Level 3
|
AZOLES
Anti-infectives · Anti-infectives
|
GANCICLOVIR
Anti-infectives · Anti-infectives · Level 3
|
CASPOFUNGIN
Anti-infectives · Anti-infectives · Level 3
|
|---|---|---|---|---|---|
| Mechanism of action | - Inhibits nucleic acid synthesis |
inhibit neurominidase resulting in impaired viral release from infected cells. Neurominidase cleaves the sialic acid on the cell membrane allowing viral budding. |
Azoles disrupt ergosterol production by interacting with 14-alpha demthylase, a cytochrome P450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of fungal cell membranes, inhibition of its synthesis leads to increased cell permeability causing leakage of contents. |
— | — |
| Absorption | Erratic intestinal absorption and low bioavailability (25%). Oral valine-esterified prodrug valacyclovir improves absorption |
— | Well absorbed orally (except miconazole) |
— | — |
| Distribution | Widely distributed |
— | Fluc – good CSF penetration |
— | — |
| Protein binding | — | — | Itra, Keto – 99% PB |
— | — |
| Metabolism | Oral valine-esterified prodrug valacyclovir is rapidly hydrolyzed in the blood |
— | Fluc not metabolized well |
— | — |
| Excretion | actively excreted in the kidneys unchanged (blocked by probenecid) |
— | Fluc – Urine unchanged |
— | — |
| Adverse Effects Toxicity | Renal |
1. Psychiatric symptoms |
Fluc: N/V/D, Abdominal pain |
— | — |
| Antimicrobial Spectrum | Herpes Simplex (1 and 2) and Varicella Zoster. |
— | Fluc: Candida |
— | — |
| Class Group | Antiviral |
Antiviral |
Antifungal |
Antiviral |
Antifungal |
| Introduction | Synthetic nucleoside analogue |
Oseltamivir and Zanamivir |
Triazoles: Fluconazole, Itraconazole, Voriconazole, Posaconazole |
— | — |
| Legacy Cicm Level | Level 3 |
Level 3 |
Level 3 |
Level 3 |
Level 3 |
| Resistance Mechanism | — | — | Fluc: Some candida species, Decreased drug concentration |
— | — |
| Special Points | — | — | potent CYP inhibitors with a wide range of drug interactions (including warfarin) |
— | — |